Related Experiment Video

Updated: Jun 18, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Sunitinib paves the way for targeted therapies in neuroendocrine tumors

Eric Raymond1, Sandrine Faivre, Pascal Hammel

  • 1Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France. eric.raymond@bjn.aphp.fr

Targeted Oncology
|November 14, 2009
PubMed

Insights

Sunitinib shows promise for pancreatic islet cell carcinomas, potentially expanding to other neuroendocrine tumors. Further trials will explore its efficacy and other novel treatments like mTOR inhibitors for tumor growth control.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pancreatic islet cell carcinomas are a type of neuroendocrine tumor.
  • Vascular Endothelial Growth Factor (VEGF)/VEGF Receptor (VEGFR) pathways are crucial for tumor angiogenesis.

Purpose of the Study:

  • To evaluate the efficacy of sunitinib in pancreatic islet cell carcinomas.
  • To explore the potential of sunitinib and other targeted therapies for various neuroendocrine tumors.

Main Methods:

  • Clinical trials investigating sunitinib efficacy.
  • Phase III trials of mTOR inhibitors.

Main Results:

  • Sunitinib demonstrated efficacy in pancreatic islet cell carcinomas.
  • This suggests potential for broader application in VEGF/VEGFR-dependent neuroendocrine tumors.

Conclusions:

  • Sunitinib's success warrants further investigation in carcinoid, poorly differentiated neuroendocrine disease, and other endocrine tumors.
  • mTOR inhibitors represent a promising therapeutic avenue for controlling tumor growth and metastasis in these diseases.

More Related Videos

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids09:43

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...